Physiomics PLC Contract award (7002H)
08 April 2022 - 4:00PM
UK Regulatory
TIDMPYC
RNS Number : 7002H
Physiomics PLC
08 April 2022
8 April 2022
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a contract by new client, the Servier Group
("Servier"), an international pharmaceutical company headquartered
in France. Cancer is one of Servier's priority therapy areas and it
has a particular focus on immunotherapies and monoclonal antibodies
for difficult to treat diseases with high unmet medical needs.
Physiomics will be providing specialist mathematical modelling
services using its Virtual Tumour software platform to model and
simulate the effect of a number of immuno-oncology combinations
involving Servier drugs in development in pre-clinical and clinical
settings. It is anticipated that the project will be completed over
the course of the next 7-8 months.
Physiomics CEO, Dr Jim Millen, commented : "We are delighted to
have been selected by Servier, one of France's leading
pharmaceutical companies with a truly global outlook as its partner
for this modelling and simulation project focused on pre-clinical
and translational modelling of a novel immuno-oncology agent in
development. We look forward to working with its talented
scientists."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 90 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUPUBUCUPPGAM
(END) Dow Jones Newswires
April 08, 2022 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024